Morgan Stanley
VIR icon

Morgan Stanley’s Vir Biotechnology VIR Stock Holding History

Morgan Stanley’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.5M Sell
2,211,077
-643,128
-23% -$6.12M ﹤0.01% 2991
2026
Q1 		$25.6M Buy
2,854,205
+175,060
+7% +$1.39M ﹤0.01% 2715
2025
Q4 		$16.2M Sell
2,679,145
-9,973
-0.4% -$59.4K ﹤0.01% 3132
2025
Q3 		$15.4M Buy
2,689,118
+1,055,428
+65% +$5.4M ﹤0.01% 3140
2025
Q2 		$8.23M Buy
1,633,690
+209,345
+15% +$1.12M ﹤0.01% 3616
2025
Q1 		$9.23M Buy
1,424,345
+300,539
+27% +$2.67M ﹤0.01% 3408
2024
Q4 		$8.25M Sell
1,123,806
-113,113
-9% -$892K ﹤0.01% 3562
2024
Q3 		$9.26M Sell
1,236,919
-886,293
-42% -$7.7M ﹤0.01% 3484
2024
Q2 		$18.9M Sell
2,123,212
-216,048
-9% -$2.07M ﹤0.01% 2725
2024
Q1 		$23.7M Buy
2,339,260
+212,981
+10% +$2.17M ﹤0.01% 2514
2023
Q4 		$21.4M Buy
2,126,279
+738,863
+53% +$6.75M ﹤0.01% 2616
2023
Q3 		$13M Buy
1,387,416
+697,690
+101% +$9.95M ﹤0.01% 2874
2023
Q2 		$16.9M Buy
689,726
+90,868
+15% +$2.28M ﹤0.01% 2640
2023
Q1 		$13.9M Sell
598,858
-578,970
-49% -$14.8M ﹤0.01% 2828
2022
Q4 		$29.8M Buy
1,177,828
+32,170
+3% +$789K ﹤0.01% 1957
2022
Q3 		$22.1M Buy
1,145,658
+64,284
+6% +$1.63M ﹤0.01% 2077
2022
Q2 		$27.5M Buy
1,081,374
+489,696
+83% +$11.4M ﹤0.01% 1934
2022
Q1 		$15.2M Sell
591,678
-639,416
-52% -$19M ﹤0.01% 2427
2021
Q4 		$51.5M Buy
1,231,094
+1,086,524
+752% +$42.6M 0.01% 1311
2021
Q3 		$6.29M Sell
144,570
-194,647
-57% -$8.43M ﹤0.01% 3435
2021
Q2 		$16M Sell
339,217
-63,424
-16% -$2.88M ﹤0.01% 2406
2021
Q1 		$20.6M Buy
402,641
+308,307
+327% +$16.6M ﹤0.01% 1874
2020
Q4 		$2.53M Buy
94,334
+53,525
+131% +$1.74M ﹤0.01% 3951
2020
Q3 		$1.4M Buy
40,809
+12,350
+43% +$532K ﹤0.01% 3963
2020
Q2 		$1.17M Buy
28,459
+10,073
+55% +$338K ﹤0.01% 4052
2020
Q1 		$630K Buy
18,386
+2,934
+19% +$78.9K ﹤0.01% 4247
2019
Q4 		$195K Buy
+15,452
New +$207K ﹤0.01% 5420

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley's VIR Position: Q2 2026 in Review

Morgan Stanley reduced its Vir Biotechnology (VIR) stake by 23% in Q2 2026, selling an estimated $6.12M and leaving 2,211,077 shares worth $22.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2991.

Morgan Stanley first reported a position in VIR in Q4 2019 and has held it in 27 quarters since. The position peaked at $51.5M in Q4 2021. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Morgan Stanley held 2,211,077 shares of Vir Biotechnology worth $22.5M as of Q2 2026.
  • Morgan Stanley sold 643,128 Vir Biotechnology shares in Q2 2026, an estimated $6.12M.
  • Vir Biotechnology made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #2991 holding.
  • Morgan Stanley first reported a position in Vir Biotechnology in Q4 2019 and has held it in 27 quarters since.
  • Morgan Stanley's Vir Biotechnology position peaked at $51.5M in Q4 2021.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.